Last reviewed · How we verify
Medtronic Cardiac Rhythm and Heart Failure — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Flecainide or Sotalol or Propafenone | Flecainide or Sotalol or Propafenone | phase 3 | Antiarrhythmic agents (Class I and Class III) | Cardiac sodium channels (Flecainide, Propafenone); cardiac potassium channels and beta-adrenergic receptors (Sotalol) | Cardiovascular |
Therapeutic area mix
- Cardiovascular · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Medtronic Cardiac Rhythm and Heart Failure:
- Medtronic Cardiac Rhythm and Heart Failure pipeline updates — RSS
- Medtronic Cardiac Rhythm and Heart Failure pipeline updates — Atom
- Medtronic Cardiac Rhythm and Heart Failure pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Medtronic Cardiac Rhythm and Heart Failure — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/medtronic-cardiac-rhythm-and-heart-failure. Accessed 2026-05-17.